NASDAQ:OYST

Oyster Point Pharma Stock Forecast, Price & News

$19.22

+0.02 (+0.10 %)

(As of 06/15/2021 12:00 AM ET)

Add

Compare

Today's Range

$18.71

▼

$19.43

50-Day Range

$16.25

▼

$21.51

52-Week Range

$15.80

▼

$33.60

Volume70,133 shs

Average Volume75,287 shs

Market Capitalization$499.30 million

P/E RatioN/A

Dividend YieldN/A

Beta-0.3

30 days | 90 days | 365 days | Advanced Chart

Receive OYST News and Ratings via Email

Sign-up to receive the latest news and ratings for Oyster Point Pharma and its competitors with MarketBeat's FREE daily newsletter.

About Oyster Point Pharma

Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company's lead product candidate is OC-01, a nicotinic acetylcholine receptor agonist that has completed Phase III clinical trial for the treatment of signs and symptoms of dry eye disease. It is also developing OC-01 for neurotrophic keratopathy. Oyster Point Pharma, Inc. was incorporated in 2015 and is headquartered in Princeton, New Jersey.

Corneal Ulcer Pipeline Analysis Demonstrates Novel Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight
June 11, 2021 | ca.finance.yahoo.com

BRIEF-Oyster Point Pharma Announces Collaboration With Adaptive Phage Therapeutics
June 10, 2021 | msn.com

Oyster Point Pharma Announces Collaboration with Adaptive Phage Therapeutics (APT) to Target Ophthalmic Diseases
June 10, 2021 | finance.yahoo.com

Oyster Point Introduces ETF Gene Therapy, First Candidate to Target Neurotrophic Keratopathy
June 3, 2021 | markets.businessinsider.com

BRIEF-Oyster Point Pharma Inc Says Preclinical Study Results And Pipeline Expansion With Enriched Tear Film Gene Therapy To Target Ocular Surface Diseases
June 3, 2021 | msn.com

Oyster Point Pharma Announces Preclinical Study Results and Pipeline Expansion with Enriched Tear Film (ETF™) Gene Therapy to Target Ocular Surface Diseases
June 3, 2021 | finance.yahoo.com

Q3 2021 EPS Estimates for Oyster Point Pharma, Inc. Lowered by Piper Sandler (NASDAQ:OYST)
May 24, 2021 | americanbankingnews.com

Analysts Offer Predictions for Oyster Point Pharma, Inc.'s FY2024 Earnings (NASDAQ:OYST)
May 21, 2021 | americanbankingnews.com

Oyster Point Pharma Reports First Quarter 2021 Financial Results and Recent Business Highlights
May 6, 2021 | finance.yahoo.com

Oyster Point Pharma to Report First Quarter 2021 Financial Results on May 6, 2021
April 30, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OYST
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.oysterpointrx.com
Phone609-382-9032
Employees62
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$7.22 per share
Price / Book2.66

Profitability

EPS (Most Recent Fiscal Year)($2.92)
Net Income$-70,520,000.00
Net MarginsN/A
Return on Equity-37.16%
Return on Assets-35.17%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares25,978,000
Market Cap$499.30 million
Next Earnings Date8/4/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.07 out of 5 stars

Medical Sector

1071st out of 2,100 stocks

Biological Products, Except Diagnostic Industry

146th out of 198 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Oyster Point Pharma.

2.2 Community Rank

Outperform Votes
Oyster Point Pharma has received 28 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Oyster Point Pharma has received 36 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Oyster Point Pharma has received 56.25% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Oyster Point Pharma and other stocks. Vote “Outperform” if you believe OYST will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OYST will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Oyster Point Pharma does not currently pay a dividend.
Dividend Growth
Oyster Point Pharma does not have a long track record of dividend growth.

2.5 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Oyster Point Pharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
36.90% of the stock of Oyster Point Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
70.73% of the stock of Oyster Point Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Oyster Point Pharma are expected to grow in the coming year, from ($3.69) to ($3.56) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Oyster Point Pharma is -6.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Oyster Point Pharma is -6.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Oyster Point Pharma has a P/B Ratio of 2.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Oyster Point Pharma (NASDAQ:OYST) Frequently Asked Questions

Is Oyster Point Pharma a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oyster Point Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Oyster Point Pharma stock.
View analyst ratings for Oyster Point Pharma or view top-rated stocks.

What stocks does MarketBeat like better than Oyster Point Pharma?

Wall Street analysts have given Oyster Point Pharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Oyster Point Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Oyster Point Pharma's next earnings date?

Oyster Point Pharma is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Oyster Point Pharma.

How were Oyster Point Pharma's earnings last quarter?

Oyster Point Pharma, Inc. (NASDAQ:OYST) released its earnings results on Thursday, May, 6th. The company reported ($0.73) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.91) by $0.18.
View Oyster Point Pharma's earnings history.

How has Oyster Point Pharma's stock price been impacted by COVID-19?

Oyster Point Pharma's stock was trading at $31.31 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OYST stock has decreased by 38.6% and is now trading at $19.22.
View which stocks have been most impacted by COVID-19.

Who are Oyster Point Pharma's key executives?

Oyster Point Pharma's management team includes the following people:

Dr. Jeffrey Nau Ph.D., MMS, Pres, CEO & Director (Age 46, Pay $833.6k)
Mr. Daniel Lochner M.B.A., Chief Financial Officer (Age 38, Pay $644.68k)
Mr. John Snisarenko M.B.A., Chief Commercial Officer (Age 57, Pay $604.68k)
Mr. George Donato, Sr. VP of CMC & Operations
Dr. Eric Carlson Ph.D., Chief Scientific Officer
Ms. Jill Andersen, Gen. Counsel & Chief Compliance Officer
Ms. Dawn Pruitt Koffler M.B.A., VP of Marketing
Ms. Nicolette Sherman, Chief HR Officer
Ms. Loni Da Silva, Sr. VP of Regulatory Affairs
Dr. Marian Macsai M.D., Chief Medical Officer of Medical Affairs

Who are some of Oyster Point Pharma's key competitors?

Some companies that are related to Oyster Point Pharma include Alector (ALEC), Immunocore (IMCR), C4 Therapeutics (CCCC), Sangamo Therapeutics (SGMO), Replimune Group (REPL), ImmunityBio (IBRX), Translate Bio (TBIO), REGENXBIO (RGNX), Cortexyme (CRTX), Valneva (VALN), Krystal Biotech (KRYS), AlloVir (ALVR), BioAtla (BCAB), Ocugen (OCGN) and Cullinan Oncology (CGEM).
View all of OYST's competitors.

What other stocks do shareholders of Oyster Point Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oyster Point Pharma investors own include OPKO Health (OPK), Pfizer (PFE), Akero Therapeutics (AKRO), The Walt Disney (DIS), Energy Transfer (ET), Fulcrum Therapeutics (FULC), Johnson & Johnson (JNJ), (NGM), Occidental Petroleum (OXY) and vTv Therapeutics (VTVT).

When did Oyster Point Pharma IPO?

(OYST) raised $85 million in an initial public offering (IPO) on Thursday, October 31st 2019. The company issued 5,000,000 shares at $16.00-$18.00 per share. J.P. Morgan, Cowen and Piper Jaffray served as the underwriters for the IPO.

What is Oyster Point Pharma's stock symbol?

Oyster Point Pharma trades on the NASDAQ under the ticker symbol "OYST."

Who are Oyster Point Pharma's major shareholders?

Oyster Point Pharma's stock is owned by many different institutional and retail investors. Top institutional investors include RTW Investments LP (7.16%), BlackRock Inc. (2.84%), Oak Ridge Investments LLC (2.24%), GW&K Investment Management LLC (1.55%), First Manhattan Co. (1.43%) and Citadel Advisors LLC (0.89%). Company insiders that own Oyster Point Pharma stock include Clare Ozawa, Daniel Lochner, Healthcare Strategic Growt Kkr, Jeffrey Nau, John Snisarenko and Vida Ventures, Llc.
View institutional ownership trends for Oyster Point Pharma.

Which institutional investors are selling Oyster Point Pharma stock?

OYST stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, Citadel Advisors LLC, Millennium Management LLC, Morgan Stanley, HighTower Advisors LLC, Northern Trust Corp, Bank of New York Mellon Corp, and Alliancebernstein L.P..
View insider buying and selling activity for Oyster Point Pharma or view top insider-selling stocks.

Which institutional investors are buying Oyster Point Pharma stock?

OYST stock was purchased by a variety of institutional investors in the last quarter, including Oak Ridge Investments LLC, BlackRock Inc., First Manhattan Co., GW&K Investment Management LLC, JPMorgan Chase & Co., Price T Rowe Associates Inc. MD, HarbourVest Partners LLC, and Geode Capital Management LLC. Company insiders that have bought Oyster Point Pharma stock in the last two years include Clare Ozawa, Daniel Lochner, Healthcare Strategic Growt Kkr, Jeffrey Nau, John Snisarenko, and Vida Ventures, Llc.
View insider buying and selling activity for Oyster Point Pharma or or view top insider-buying stocks.

How do I buy shares of Oyster Point Pharma?

Shares of OYST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Oyster Point Pharma's stock price today?

One share of OYST stock can currently be purchased for approximately $19.22.

How much money does Oyster Point Pharma make?

Oyster Point Pharma has a market capitalization of $499.30 million. The company earns $-70,520,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis.

How many employees does Oyster Point Pharma have?

Oyster Point Pharma employs 62 workers across the globe.

What is Oyster Point Pharma's official website?

The official website for Oyster Point Pharma is www.oysterpointrx.com.

Where are Oyster Point Pharma's headquarters?

Oyster Point Pharma is headquartered at 202 CARNEGIE CENTER SUITE 109, PRINCETON NJ, 08540.

How can I contact Oyster Point Pharma?

Oyster Point Pharma's mailing address is 202 CARNEGIE CENTER SUITE 109, PRINCETON NJ, 08540. The company can be reached via phone at 609-382-9032 or via email at [email protected]

This page was last updated on 6/15/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here